Patients
15.3 % of adults
Obesity (adults), Spain, 2024 (WHO).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Chandani Patel
Spain Oral GLP-1 Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$925.1 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $68.7 Mn | — | — |
| 2025 (base) | $90.0 Mn | +$21.2 Mn | — |
| 2026 (forecast) | $117.8 Mn | +$27.8 Mn | +30.9% |
| 2027 (forecast) | $154.1 Mn | +$36.4 Mn | +71.3% |
| 2028 (forecast) | $201.8 Mn | +$47.6 Mn | +124.3% |
| 2029 (forecast) | $264.1 Mn | +$62.3 Mn | +193.6% |
| 2030 (forecast) | $345.7 Mn | +$81.6 Mn | +284.3% |
| 2031 (forecast) | $452.6 Mn | +$106.8 Mn | +403.1% |
| 2032 (forecast) | $592.4 Mn | +$139.8 Mn | +558.5% |
| 2033 (forecast) | $775.5 Mn | +$183.1 Mn | +762% |
| 2034 (forecast) | $1.02 Bn | +$239.6 Mn | +1,028.4% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $90.0 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $1.02 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 30.9% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug, application and end user (see all) |
| Key players | Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Structure Therapeutics, Viking Therapeutics (see all) |
| Regulator in Spain | AEMPSSource: Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Oral GLP-1 drugs deliver GLP-1 based therapy as a tablet instead of an injection, making treatment easier for people with diabetes or obesity.
Key segments of the oral GLP-1 Drugs market include drug (Oral Semaglutide, Orforglipron and Danuglipron) and application (Type 2 Diabetes and Obesity).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the oral GLP-1 Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the oral GLP-1 Drugs market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the oral GLP-1 Drugs market. Long-term safety data and lifestyle support are still needed for many patients.
The oral GLP-1 Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AEMPS, the Spanish Agency of Medicines and Medical Devices.[1] The National Health System (SNS), run by the regions, gives universal public care.[2] Obesity (adults): 15.3% of adults in 2024, the latest WHO figure for Spain.[3]
[1] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[2] Spanish Ministry of Health. Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 20 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for oral GLP-1 Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Spain.
What doctors and scientists are doing in Oral GLP-1 Drugs right now, from free public sources.
15.3 % of adults
Obesity (adults), Spain, 2024 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Obesity (adults) (% of adults). Retrieved 19 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.
From our blog
Spain · 3 shared keywords
Spain · 1 shared keyword
Spain · 1 shared keyword
Spain · 1 shared keyword
Spain · 1 shared keyword
Spain · 1 shared keyword
Medical Devices · Spain
Medical Devices · Spain
Medical Devices · Spain
Medical Devices · Spain
Healthcare Services · Spain
Digital Health · Spain